medigraphic.com
Colegio de Medicina Interna de México.

2012, Number 5

<< Back Next >>

Med Int Mex 2012; 28 (5)

Fixed Dose Combination: A New Treatment Option for Type 2 Diabetes Mellitus

Martínez GK, Díaz SJ

Language: Spanish
References: 34
Page: 483-490
PDF size: 284.42 Kb.


ABSTRACT

Diabetes mellitus type 2 is a chronic but controllable degenerative disease. The natural history of its evolution brings like consequence that many patients progress inevitably in spite of the treatment. The main classes of antidiabetics used in monotherapy induces, in the long term, glycemic increase. For those patients that requires a combination of oral antidiabetics exists, at the moment, several combinations of fixed doses. Two or more therapeutic agents with complementary mechanisms of action allows to optimize the fulfillment and attachment to the treatment. The largest reduction of HbA1c is achieved with saxagliptin + prolonged liberation metformin.


REFERENCES

  1. Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;1047- 1053.

  2. Villalpando S, De la Cruz V, Rojas R, Avila MA, Gaona B, Rebollar R, Hernández L. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population. A probabilistic survey. Salud Publica de Mexico 21010;52(1)

  3. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249- 1258.

  4. Kahn SE, Haffner SM, et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.

  5. Levy J, et al. Beta cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: 10 year follow up of the Belfast Diet Study. Diabet Med 1998;15:290-296.

  6. Cook MN, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000.

  7. Inzucchi S, et al. Management of Hyperglycemia in Type 2 Diabetes: A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1-16.

  8. Benford M, et al. Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance. Adv Ther 2012;29(1):26-40.

  9. Garber AJ, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201-208.

  10. Perez A., et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25:2915-2923.

  11. Rosenstock J, et al. Initial treatment with rosiglitazone/ metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-660.

  12. Goldstein BJ, et al. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890-903.

  13. Moses R, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-124.

  14. Goldstein BJ. Effect of initial combination therapy with sitagliptin, a dipeptidylpeptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.

  15. Jadzinsky M, et al. Saxagliptin given in combination with metofrmin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.

  16. Bosi E., Camisasca et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-895.

  17. Goldstein BJ, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycaemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987.

  18. Scott LJ, et al. Linagliptina: in type 2 diabetes mellitus. Drugs 2011;71(5):611-24.

  19. Bristol Myers Squibb-AstraZeneca EEIG. Onglyza (saxagliptin) 2.5, 5mg film-coated tablets: summary of product characteristics. Disponible en: URL:http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR__Product information/ human/001039/WC500044316.pdf.

  20. Hollander PA, et al. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122(3):71-80.

  21. European Medicines Agency. CHMP assessment report for Onglyza. Disponible en: URL:http://www.ema.europa.eu/docs/ en_GB/document:library/EAPAR__Public_assessment_report/ human/001039/WC500044319.pdf

  22. Natali A, et al. Vascular effects of improving metabolic control with metfrormin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27(6):1349-57.

  23. Turner RC, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA 1999;281(21):2005-12.

  24. Gibaldi M, et al. Pharmacokinetics in clinical practice. I. concepts. JAMA 1976;235(17):1864-7.

  25. Lowell BB, et al. Mitochondrial dysfunction and type 2 diabetes. Science 2005:307(5708):384-7.

  26. Timmis P, et al. Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation. Clin Pharmacokinet 2005;44(7):721-729.

  27. Hebden JM, et al. Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit forumulations. Eur J Gastroenterol Hepatol 1999;11:1379-85.

  28. Glucophage (metformin hydrochloride) and glucophage XR (metformin hydrochloride extended-release tablets) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2002.

  29. Boulton D, et al. Bioequivalence of saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects. Clin Drug Investig 2011;31(9):619-630.

  30. Guillausseau PJ. Influence of oral antidiabtic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29(1):79-81.

  31. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformininduced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122(2):112-20.

  32. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformina in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010;2:1.

  33. Blonde L, et al. Gastrointestinal tolerabililty of extended-release metformin tablets compared to inmmediate-release metformin tablets: results of retrospective cohort study. Current Medical Research and Opinion 2004;20(4):565-572.

  34. Benford M., et al. Fixed-Dose Combination Antidiabetic Therapy: Real-World Factors Associated with Prescribing Choices and Relationship with Patient Satisfaction and Compliance. Adv Ther 2012;29(1):26-40.




2020     |     www.medigraphic.com